



DEPARTMENT OF HEALTH & HUMAN SERVICES

National Institutes of Health
Bethesda, Maryland 20892

December 19, 2017

S. C. Johnston, MD, PhD
The University of Texas at Austin
Austin, TX 78712

Dear Dr. Johnston:

I am writing to confirm that the NINDS-appointed Data and Safety Monitoring Board (DSMB) for your clinical trial, "Platelet-Oriented Inhibition in New TIA and minor ischemic stroke" (POINT), met by teleconference yesterday.

The DSMB recommended to the NINDS that the trial discontinue enrollment and complete follow-up of patients already randomized in the trial. The NINDS has accepted the DSMB's recommendation.

The DSMB and NINDS are grateful to all the patients who participated in this trial and all the investigators, coordinators and staff working on this important research study.

Sincerely,

A handwritten signature in black ink, appearing to read "Peter R. Gilbert".

Peter R. Gilbert, Sc. M.
Clinical Research Project Manager
Division of Clinical Research
National Institute of Neurological Disorders and Stroke

cc: J. Donald Easton, MD
UCSF